ABSTRACT: With the current COVID-19 outbreak, it has become essential to develop efficient methods for the treatment and detection of this virus. Among the new approaches that could be tested, that relying on nanotechnology finds one of its main grounds in the similarity between nanoparticle (NP) and coronavirus (COV) sizes, which promotes NP−COV interactions. Since COVID-19 is very recent, most studies in this field have focused on other types of coronavirus than COVID-19, such as those involved in MERS or SARS diseases. Although their number is limited, they have led to promising results on various COV using a wide range of different types of nanosystems, e.g., nanoparticles, quantum dots, or nanoassemblies of polymers/proteins. Additional efforts deserve to be spent in this field to consolidate these findings. Here, I first summarize the different nanotechnology-based methods used for COV detection, i.e., optical, electrical, or PCR ones, whose sensitivity was improved by the presence of nanoparticles. Furthermore, I present vaccination methods, which comprise nanoparticles used either as adjuvants or as active principles. They often yield a better-controlled immune response, possibly due to an improved antigen presentation/processing than in non-nanoformulated vaccines. Certain antiviral approaches also took advantage of nanoparticle uses, leading to specific mechanisms such as the blocking of virus replication at the cellular level or the reduction of a COV induced apoptotic cellular death.

INTRODUCTION

With the spread of the COVID-19 epidemic and the disorders that it has caused, i.e., an increased mortality rate, a saturation of the hospital infrastructures, and a sudden major slow-down of the world economy, it appears essential to better understand the behaviors of coronaviruses (COV) and to develop efficient methods for their detection and destruction. To this end, an enormous research effort has been implemented worldwide, which mainly relies on drug repositioning, i.e., testing as COV treatments drugs such as chloroquine and remdesivir or their derivatives, which have shown their efficacy against other diseases than COV, i.e., malaria and HIV. Such an effort could be complemented by other approaches, e.g., in the field related to nanotechnologies for COV treatment. Indeed, the sizes of these viruses are similar to those of nanoparticles, hence promoting NP-COV interactions and potentially resulting in similar behaviors between NP and COV. Thus, it has been suggested that certain drawbacks of standard attenuated/inactivated vaccines, such as their pathogenic virulence or weak immune responses, could be overcome by using nanoformulations (NF). This is due to sizes, shapes, functionalities, and antigen presentation-processing that could be favorably adjusted in NF, potentially yielding a more efficient and better-controlled immune system response for nanoformulated than non-nanoformulated drugs. Here, methods using various types of nanotechnologies that have been tested for diagnosis and treatment of COV are reviewed. The different fields in which nanotechnologies could help to bring a solution linked to the COVID-19 crisis are (i) the development of a cheap and rapid test for diagnosing COVID 19 that could be deployed worldwide over the entire population, (ii) the prevention of virus replication and viral RNA synthesis, for example, by using nanoparticles that block the interaction between COVID 19 and the cellular receptor ACE-2, (iii) the development of new nanoparticle-based-vaccine, and (iv) the restoration of innate immunity among infected patients. Nanomaterial safety is a prerequisite for their administration to humans. To ensure this, regulatory agencies have set up specific regulations with dedicated biocompatibility tests. Although it is difficult to consider nanomaterial safety in general terms due to the huge diversity of these materials, certain nanoparticles such as those composed of iron oxide have been granted authorization for human injection, and could therefore potentially be tested clinically against COVID 19. Due to the
recent outbreak of COVID-19, the majority of studies relates to other types of coronaviruses than COVID-19, i.e., human COV such as those associated with Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) diseases, and animal COV such as Feline Coronavirus (FCOV), Porcine Epidemic Diarrhea Viruses (PEDV), and Infectious Bronchitis Virus (IBV). The use of similar treatment strategies for COVID-19 than for these other COV may be foreseen, but even so, such therapies remain exploratory, and no effective MERS/SARS vaccine has yet been put in place to the author’s knowledge.

Figure 1. Schematic diagrams showing different examples of nanomaterial-based COV detection methods. (a) Fluorescent Zr QDs and magnetic nanoparticles are conjugated with antibodies that specifically bind to COV. In the presence of COV, a magnetic fluorescent complex is formed, which is isolated magnetically and detected by fluorescence measurements. (b) Nanotrap is used to concentrate COV and improve their stability, hence facilitating their detection. (c) Reverse transcription PCR is carried out in the presence of nanoparticles, improving the efficacy of the polymerase chain reaction, and resulting in a better detection sensitivity of this method. (d) COV detection method, which is based on the interactions between complementary DNA originating from COV and acpnPNA probe at the surface of Ag NP, which results in a separation between Ag NPs, and a yellow color associated with the luminescence of well dispersed Ag NPs, further revealing COV presence.

I. GENERALITIES ABOUT CORONAVIRUS TREATED/DETECTED WITH NANOTECHNOLOGIES, I.E., SARS, MERS, IBV, FCOV, TEGV, AND PEDV

Coronavirus (COV) comprises 50−150 nm viruses, which are made of nucleocapsid (N) proteins attached to positive single-stranded RNA covered by an envelope, which consists of a lipid bilayer containing membrane (M), envelope (E), and spike (S) proteins. Under simplified terms, coronavirus replication in the organism is characterized by the following chain of events: (i) attachment of viral spike (S) glycoprotein to its complementary host cell receptor, (ii) virus endocytosis in cells, (iii) virus uncoating, (iv) virus replication, and (v) virus release. COV can infect humans (COVID-19, SARS, and MERS), chickens (IBV), cats (FCov), or pigs (PEDV and TGEV). It was suggested that some coronavirus could be transferred from one species to another. For example, it was reported that SARS and MERS could originate from bats or camels, which seems to be based on viral ARN similitudes observed between these different species. Following an incubation period, coronaviruses affect specific parts of the organism such as tract or gastrointestinal system, potentially resulting in severe diseases such as pneumonia. Coronavirus detection is usually carried out through ELISA, immunofluorescence, PCR, and/or chest X-rays. While coronavirus infection can be avoided through vaccination for PEDV, vaccines have not yet been developed for SARS and MERS.

II. NANOTECHNOLOGIES TO PREVENT COVID-19 INFECTION

Transmission of COVID 19 occurs through droplets containing the virus that are emitted by an infected person through coughing, sneezing, or talking. These droplets are either directly transmitted to another person in proximity or are evaporated to end up as dried nuclei located at the surface of an object such as a knob, a button, a table, or a door. From a general standpoint, virus transmission can be prevented by isolating the infected person, by cleaning contaminated objects, by frequently washing hands, or by wearing personal protection equipment. This latter aspect, notably the necessity (or not) to wear masks, has been the topic of contradictory recommendations from the authorities. This is essentially due the lack of knowledge on the efficacy of existing masks to filter COVID 19 virus. With the size of COVID 19 being nanometric, nanotechnological tools can help to clarify this issue. To this aim, a study has been led to compare the filtering efficacy of common masks made of cotton, silk, chiffon, flannel, and their combination. It concluded that a
mask made of a single fabric or containing holes was not optimal for filtering COVID 19, while that comprising a combination of cotton and silk, cotton and chiffon, or cotton and flannel could filter 80–90% of the virus, where such enhanced efficacy was attributed to a mechanism relying on a combination of mechanical and electrostatic interactions between the virus and the fabrics that could only be reached by combining materials. Another group used electrostatically charged PVDF nanofiber filters to capture the deadly airborne coronavirus.20,21 A third approach consisted of depositing nanostructured graphene at the surface of surgical masks. Such masks became superhydrophobic with a temperature that could reach 80 °C under sunlight illumination, making them sterilizable and reusable, an important aspect given the necessity to be able to easily decontaminate masks to avoid virus spreading through mask misuses.22

III. NANOTECHNOLOGIES USED FOR CORONAVIRUS DIAGNOSIS

To avoid false positive/negative that can occur in standard detection methods of COV such as PCR, ultrasensitive nanodetection methods have been developed. Nanotechnology-based COV detection methods are summarized in Figure 1. They first rely on highly sensitive optical mechanisms. The latter can be a measurement of fluorescence at 412 nm of a complex made of Zr QDs bound to anti-COV antibodies linked to COV, following magnetic isolation.23 It can also be fluorescence detection of green fluorescent protein (GFP) comprising a complex formed by SARS virus proteins attached to Au NP whose fluorescence is different from that of free GFP.24 It can be based on several calorimetric assays enabling COV detection by using Au associated with various entities such as double-stranded DNA that specifically bind to COV,25 antibodies acting against IBV spike proteins,26 or monoclonal antibodies (mAbs) activated against PEDV,27 or by using Ag NP attached to acpcPNA, which remain dispersed in the presence of complementary COV derived DNA, giving rise to a detectable color change.28 Au nanoislands were also functionalized with specific DNA strands that bind to SARS-COV-2 nucleic acids under heating produced by laser illumination followed by Au NP plasmon absorption, enabling COVID-19 detection at virus concentration as low as 0.22 pM.29 Another type of COV detection method relies on the use of nanotraps that capture COV, improving their stability and enabling their detection over a long period of time.30 It was also reported that COV could be detected with a biosensor made of carbon electrodes that comprise Au NP associated with viral spike proteins, whose response, i.e., peak current position/intensity, depends on the presence (or not) of MERS-COV.31 In another approach, a field-effect transistor (FET) coated with graphene sheets attached to antibodies that specifically recognize COVID 19 spike proteins enabled the detection of these proteins in different media (phosphate-buffered saline, culture medium, clinical samples) down to COVID 19 concentrations of 1 fg/mL.32 Finally, the efficacy of PCR, which is the most widespread method of COV detection, can be improved by using nanoparticles, either through the simultaneous (duplex) detection of two virus types such as DNA and RNA viruses, e.g., using nanoparticles conjugated to specific probes of these viruses,33,34 or by making the polymerase chain reaction more efficient in the presence than absence of nanoparticles.35,36

Figure 2. Schematic diagram presenting various types of nanotherapies used against COV, which are categorized as vaccines or antiviral drugs, and comprise various types of Ag nanomaterials, i.e., free NP/NW or NP attached to graphene nanosheets, diphyllin inserted within PEG—PLGA vesicles, various nanomaterials, i.e., Au NP, polymers such as PEI, PLGA, or chitosan, bound to COV antigens, nanoassemblies comprising COV antigens, as well as an interesting nanocage used as vaccine despite its lack of COV antigen.
Table 1. Vaccines against COV Based on Various Nanotechnologies

| Nanomaterial backbone | Size (nm) | Shape | ZP | Active substance | COV type | Admin route | In vivo data | refs |
|-----------------------|-----------|-------|----|-----------------|----------|-------------|--------------|-----|
| Gold                  | 16 nm     | sphere | 20 mV | Antigen of gastroenteritis COV | SARS     | Subcutaneous | Mice immunized with Gold-COVantigen: | 47  |
|                       | 100−600 nm| sphere |      | Killed vaccine antigen (KVA) | PEDV     | Intranasal   | Pregnant sows inoculated with PLGA-Kag → passively immunized suckling piglets | 48  |
| chitosan              | 286 nm    | sphere | 10 mV | Inactivated infectious bronchitis virus (IBV) | IBV      | Intranasal | Chicken immunized with chitosan-IBV: | 49  |
|                       | 210 nm    | sphere | 20 mV | DNA expressing COV protein (DNA-COV) | SARS     | Intranasal   | Mice immunized with chitosan-DNA-COV: | 50  |
| PEI                   | 195 nm    |        | 10 mV | pci-S: SARS DNA Vaccine | SARS     | Intranasal   | Mice immunized with PEI-pci-S: | 51  |
| chitosan              | 122 nm    | sphere | 20 mV | Antigen of infectious bronchitis virus (A-IBV) | IBV      | Intranasal | Chicken immunized with chitosan—A-IBV: | 52  |
|                       | 25 nm     |        | 10 mV | Spike proteins of COV | SARS     | Intramuscular | Mice immunized with Nano-COV-P inoculated into Balb/C mice: | 53, 54 |
|                       | 80 nm     |        | 10 mV | Spike proteins of COV | SARS     | Intranasal | Mice immunized three times with (Nano-COV-P): | 55  |
| Ferritin (FR); scaffold of nanoassembly SSG; linker between FR and RBD | 28−30 nm | sphere | 1090 kDa | Receptor binding domain (RBD) of COV | MERS     | Intramuscular | Mice immunized 2 times with RBD-[SSG]-FR: | 56  |
|                       | 23 nm     |        | 10 mV | Epitope of COV spike proteins | IBV      | Intranasal   | → DC targeting + both humoral and cellular immune responses | 57  |
|                       | 25 nm     | sphere | 20 mV | COV spike protein | SARS     | Interperitoneal | Mice immunized with COV-SAPN | 59  |
| Incorporation of SARS peptide in synthetic NP (SARSP-N) | Sphere |        | 20 mV | COV peptide | SARS     | Interperitoneal | Mice inoculated with PCN: | 61  |
general, compared to standard PCR, nano-PCR presents the advantages of requiring a simplified operating mode, i.e., DNA/RNA extraction, RNA purification, and reverse transcription may not be needed, of resulting in a better sensitivity, and of avoiding cross-contamination with other viruses.

IV. VACCINES CONTAINING NANOMATERIALS TESTED AGAINST COV INFECTION

A series of nanoformulated anticonvirus vaccines, which are presented in Figure 2, were developed. They often resulted in a better efficacy than their non-nanoformulated counterparts. Such vaccines contain a backbone made of gold nanoparticles, polymers such as PLGA, chitosan, and PEI, or protein assemblies. This backbone is conjugated or associated with an active principle consisting of COV antigen, inactivated or destroyed COV, DNA expressing certain COV proteins, or specific COV proteins such as spike ones (Table 1). Although a nanoparticulate formulation usually refers to a material whose size is between 1 and 100 nm, the sizes of these vaccines could exceed this upper limit, ranging from 12 to 600 nm (Table 1). Other specific properties of these vaccines include their charge, which is positive when it is measured apparently corresponding to the charge of their coating material, and their shape, which is most often reported as spherical (Table 1). When animals such as mice and chicken were immunized with vaccines, it led to a production of cytokines, i.e., essentially γ-IFN, IL-1β, IL-2, and IL-6, as well as an activity of certain immune cells such as macrophages, lymphocytes, and B cells, which were more important using formulated than non-nanoformulated vaccines. To the author’s knowledge, it was not reported whether the immune reaction was dominated by a humoral or cell mediated response. In fact, both types of responses seem to occur, resulting in some cases in the restoration of respiratory body activity and protection of specific body parts such as the trachea. Whereas in most cases, a specific antigen originating from COV was inserted in the nanoformulation to trigger a reaction against the virus, an interesting study presented a nanoformulated system, i.e., a protein cage nanoparticle (PCN), which was devoid of such antigens. Following its injection to mice, it resulted in the production of antiviral antibodies, and led to an increase in mouse survival. Beyond the explanation provided, i.e., the development of inducible bronchus-associated lymphoid tissue (iBALT) in the lung that triggered T and B cell responses, the most interesting aspect of this study seems to lie in the fact that a specific antigen may not be absolutely necessary for a nanoformulated COV vaccine to be efficient. Very recently, a clinical trial was launched to study the efficacy of a vaccine against COVID 19 containing m-RNA lipid nanoparticles. Its outcome is pending.

V. ANTIVIRAL NANOMATERIAL DRUGS STUDIED TO FIGHT CORONAVIRUS

Even so, nanoformulated vaccines aimed at triggering an immune response against COV, while antiviral nanoformulations should prevent certain interactions between virus and cells or their consequences, these two types of mechanisms, whose details are provided in Figure 3, can coexist together. The study of the response of the immune system was carried out in vivo to be able to monitor the production of specific antibodies acting against COV, whereas antiviral behaviors were examined in vitro to decipher the mechanisms of virus interactions with cells. As presented in Figure 2 and Table 2, antiviral nanoformulations
were reported to be of essentially four types: (i) the antiviral agent diphyllin encapsulated in PEG−PLGA copolymers of 40 nm,39,40 (ii) Ag nanoparticles of 7.5 nm bound to graphene nanosheets,41 (iii) Ag2S nanoclusters of 3.2 nm,42 and (iv) several Ag based nanomaterials including Ag nanoparticles of 20 nm and Ag nanowires of 60 and 400 nm diameters.43 The antiviral activity of these nanoformulations against COV was first achieved by blocking cellular endosomal acidification, which seems to be an essential step in COV replication, using an ATPase blocker, diphyllin, which is nanoformulated to yield a good solubility and be released in a sustainable manner. It resulted in efficient COV replication blockage in fcwf-4 cells.39,40

Second, inhibition of the synthesis of viral RNA was reached by using the various types of Ag nanomaterials mentioned above.41−43 Third, antiviral activity could be associated with a certain level of cellular immune response, as highlighted by the expression of pro-inflammation cytokines following cellular exposure to Ag NP.42 Fourth, it could correspond to a reduction of COV-induced apoptotic cellular death in the presence of Ag nanomaterials.43 Finally, for the treatment of COVID 19, it has

Figure 3. Schematic diagram presenting the proposed mechanisms of action of the various nanomaterials, which are mainly based on the stimulation of various parts of the immune system against COV for vaccines and on the inhibition of COV replication at cellular level or the prevention of COV-induced apoptotic cellular death for antiviral drugs.

Table 2. Antiviral Drugs against COV Relying on Various Nanotechnologies

| Nanomaterial backbone | Size (nm) shape | Active substance | COV type | Admin route | In vitro/in vivo data | refs |
|-----------------------|----------------|-----------------|----------|-------------|----------------------|------|
| PEG−PLGA              | 40 nm          | diphyllin       | FCoV     | NA          | In fcwf-4 cells, PEG−PLGA-diphyllin reduces endosomal acidification: → Inhibits V-ATPase and virus replication | 39, 40 |
| Graphene-Ag           | 7.5 nm Ag NP   | Ag NP           | FCoV     | NA          | In fcwf-4 cells, GO-Ag inhibits virus infection of FCoV → Mechanism warrants further studies | 41   |
| Ag2S Nanoclusters     | 3.2 nm Sphere  | Ag2S nanoclusters | PEDV     | NA          | In Vero cells, Ag2S NC reduce PEDV infection → inhibits production of viral RNA and viral budding → Activates IFN-stimulating genes pro-inflammation cytokines | 42   |
| Ag NP and NW          | 60−400 diam (NW) <20 nm (NP) | Ag NP/NW | TGEV | NA          | In ST cells, Ag NP/NW reduce TGEV infection → ↓ number of apoptotic cells induced by TGEV → Regulation of p38/mitochondria-caspase-3 signaling pathway | 43   |

aZeta potential. bRoute of administration of nanomaterials.
been suggested to use certain nanomaterials with a structure similar to that of ACE-2 receptor, which plays a central role in COVID-19 cellular internalization and replication. Such materials consisted of peptid inhibitors derived from the protease domain of ACE-2, which specifically bind to COVID-19 receptor binding domains, hence potentially preventing COVID-19 multiplication in cells.5

VI. INDIRECT TREATMENT/DETECTION METHODS OF COVID-19

In addition to methods of direct virus destruction presented above, the bases of other therapeutic approaches have been introduced, whose mechanisms of action rely on the correction of certain dysfunctions of the organism due to the virus. For example, the modification of the microbiome induced by COVID-19, which is suspected through several signs among infected patients such as diarrhea, a relatively long incubation time of 2–5 days of the virus, the transmission of the virus through fecal route, but is not formally demonstrated, could be examined. On one hand, nanomaterials could be used for the detection of compounds or inflammatory proteins originating from a disturbed microbiota, which could indirectly reveal the presence of COVID-19. On the other hand, nanomaterials could serve to improve the local delivery of drugs in the gut, which would fight against COVID-19 by restoring healthy activity of the microbiome.46

CONCLUSION

In this topical review, I have highlighted the potential of certain nanotechnologies for improving the detection and destruction of coronavirus. Concerning COV detection using nanomaterials, it either allows specific COV binding at NP surface or improves PCR efficacy, generally leading to better sensitivity compared with other detection methods. Compared with their non-nanoformulated counterparts, nanodrugs display a series of advantages in the fight against COVID-19 such as an improved drug safety and solubility,5 better virus inhibition,5 and more efficient immune response and organ targeting,3,4 as summarized in Figure 4. In addition, when they are included in vaccines, they can replace standard adjuvants. The appealing properties of these nanomaterials have been highlighted not only through their use in new vaccination methods but also in the context of specific antiviral treatments, where nanoformulated antiviral drugs could block virus replication, trigger an anti-COV immune response, or prevent COV-induced apoptotic cellular death.

In order to develop nanotechnology based treatments for COVID-19, certain additional aspects that have not been mentioned in the literature should be examined. They notably concern the interactions between nanomaterials and cells or cell
receptors that should not only prevent virus replication but also yield minimal cellular toxicity. These two aspects should probably be studied in parallel to evaluate the benefit/risk ratio of nanomaterial-based treatment against COVID 19. Furthermore, the efficacy of nanotechnology-based vaccines or antiviral drugs against COVID 19 should be tested on suitable animal models such as hACE2 transgenic mice, a task that has not been undertaken to the author’s knowledge. The fact that we urgently need a treatment against COVID 19 should not make us skip some essential steps in drug development. It appears insufficient to start a human clinical trial based only on the observation of cellular drug efficacy. Drug assessment on animals is essential to examine the conditions under which a drug is efficient, notably to determine preclinically the dose or administration route of anti-COV 19 nanoformulated drugs that could potentially result in treatment efficacy on humans.

**AUTHOR INFORMATION**

**Corresponding Author**

Edouard Alphandéry  —  Paris Sorbonne Université, Muséum National d’Histoire Naturelle, UMR CNRS 7590, IRD, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, 75005 Paris, France; Nanobactérie SARL, 75116 Paris, France; Institute of Anatomy, UZH University of Zurich, CH-8093 Zurich, Switzerland; orcid.org/0000-0002-2952-2270; Phone: 0033632697020; Email: edouardalphandery@hotmail.com

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.bioconjchem.0c00287

**Notes**

The author declares the following competing financial interest(s): The author has been working in the start-up E9309 and Nanoglioma E11778), the AIR program (CIFRE 2015/976), the Eurostars programs (Nanoneck-2 Me, ANR, https://pubs.acs.org/10.1021/acs.bioconjchem.0c00287), and has been undertaking a research for the Nanoform:PEC research team with the support of the BPI ("banque publique d’investissement, France"), the region of Paris ("Paris Région Entreprise, France"), the French Research Tax Credit program ("crédit d’impôt recherche"), the incubator Paris Biotech Santé, the ANRT (CIFRE 2014/0359, CIFRE 2016/0747, CIFRE 2013/0364, CIFRE 2015/976), the Eurostars programs (Nanoneck-2 E9309 and Nanoglioma E11778), the AIR program ("aide à l’innovation responsable") from the region of Paris (A1401025Q), the ANR ("Agence Nationale de la Recherche") Méfito, as well as the Universities Paris 6 and Paris 11. We also would like to thank the Nomis Foundation and Markus Reinhard for their support.

**ABBREVIATIONS**

ACE-2, Angiotensin-converting enzyme 2; COV, Coronavirus; COVID or COVid, Coronavirus disease; COVID 19, Coronavirus disease appearing in 2019; ELISA, Enzyme linked immune-sorbert assays; FCOV, Feline coronavirus; HIV, Human immunodeficiency virus; IBV, infectious bronchitis virus; IMA, Immuno-chromatic assay; MERS, Middle East Respiratory Syndrome; NM, Nanomaterial; NF, Nanofomulation; NP, Nanoparticle; PCR, Polymerase chain reaction; PEDV, Porcine epidemic diarrhea virus; PEG, Polyethylene glycol; PEI, Polyethylenimine; PLGA, Poly(lactic-co-glycolic acid); QD, quantum dot; SARS, Severe Acute Respiratory Syndrome; SEP, Self-assembled proteins; TGEV, Transmissible gastroenteritis coronavirus

**REFERENCES**

(1) Pang, J., Wang, M. X., Ang, I. Y. H., Tan, S. H. X., Lewis, R. F., Chen, J. L. P., Gutierrez, A. R., Gwee, S. X. W., Chua, P. F. Y., Yang, Q., Ng, X. Y., Yap, R. K. S., Tan, H. Y., Teo, Y. X., Tan, H. Y., Cook, A. R., Yap, J. C. H., and Hsu, L. Y. (2020) Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. J. Clin. Med. 9, 623.

(2) Liu, Z., Liu, S., Cui, J., Tan, Y., He, J., and Zhang, J. (2012) Transmission Electron Microscopy Studies of Cellular Responses to Entry of Virions: One Kind of Natural Nanobiomaterial. Int. J. Cell Biol. 2012, 1.

(3) Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., and Archambault, D. (2019) Nanoparticle-Based Vaccines Against Respiratory Viruses. Front. Immunol. 10, 22.

(4) Dhakal, S., and Renukaradhya, G. J. (2019) Nanoparticle-based vaccine development and evaluation against viral infections in pigs. Vet. Res. 50, 90.

(5) Han, Y., and Kral, P. (2020) Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2. ACS Nano 14, 5143.

(6) Alphandéry, E. (2019) A discussion on existing nanomedicine regulation: Progress and pitfalls. Applied Materials Today 17, 193.

(7) Alphandéry, E. (2019) Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease. Nanotoxicology 13, 573.

(8) Schoeman, D., and Fielding, B. C. (2019) Coronavirus envelope protein: current knowledge. Virol. J. 16, 69.

(9) Neuman, B. W., Adair, B. D., Yoshioka, C., Quispe, J. D., Orca, G., Kuhn, P., Milligan, R. A., Yeager, M., and Buchmeier, M. J. (2006) Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy. J. Virol. 80, 7916.

(10) Fehr, A. R., and Perlman, S. (2015) Coronavirus: An Overview of Their Replication and Pathogenesis. Methods Mol. Biol. 1282, 1–23.

(11) Banerjee, A., Kulcsar, K., Misra, V., Frieman, M., and Mossman, K. (2019) Viruses 11, 41.

(12) Hemida, M. G., Chu, D. K. W., Poon, L. L. M., Perera, R. A. P. M., Alhammadi, M. A., Ng, H. Y., Siu, L. Y., Guan, Y., Alineaem, A., and Peiris, M. (2014) MERS Coronavirus in Dromedary Camel Herd, Saudi Arabia. Emerging Infect. Dis. 20, 1231.

(13) Lessler, J., Reich, N. G., Brookmeyer, R., Perl, T. M., Nelson, K. E., and Cummings, D. A. T. (2009) Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect. Dis. 9, 291.

(14) Mahony, J. B. (2008) Detection of Respiratory Viruses by Molecular Methods. Clin. Microbiol. Rev. 21. 716–747.

(15) Lee, S. H., Yang, D. S., Lee, S. H., and Cho, I. C. (2018) Efficacy of inactivated variant porcine epidemic diarrhea virus vaccines in growing pigs. Clin. Exp. Vaccine Res. 7, 61.

(16) Cui, J., Li, F., and Shi, Z. L. (2019) Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181.

(17) Kim, J. Y., Song, J. Y., Yoon, Y. K., Choi, S. H., Song, Y. G., Kim, S. R., Son, H. J., Jeong, S. Y., Choi, J. H., Kim, K. M., Yoon, H. J., Choi, J. Y., Kim, T. H., Choi, Y. H., Kim, H. B., Yoon, J. H., Lee, J., Eom, J. S., Lee, S. O., Oh, W. S., Choi, J. H., Yoo, J. H., Kim, W. J., and Cheong, H. J. (2015) Middle East Respiratory Syndrome Infection Control and Prevention Guideline for Healthcare Facilities. Infect. Chemother. 47, 278.

(18) Huang, H., Fan, C., Li, M., Nie, H.-L., Wang, F.-B., Wang, H., Wang, B., Xia, J., Zheng, X., Zuo, X., and Huang, J. (2020) COVID-19: A Call for Physical Scientists and Engineers. ACS Nano 14, 3747.

(19) Konda, A., Prakash, A., Moss, G. A., Schmolldt, M., Grant, G. D., and Guha, S. (2020) Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. J. Aerosol Sci. 136, 105729.

(20) Leung, W. W., and Sun, Q. (2020) Electrostatic Charged Nanofiber Filter for Filtering Airborne Novel Coronavirus (COVID-19) and Nano-aerosols. Sep. Purif. Technol. 250, 116886.

(21) Leung, W. W., and Sun, Q. (2020) Charged PVDF multilayer nanofiber filter in filtering simulated airborne novel coronavirus
(COVID-19) using ambient nano-aerosols. Sep. Purif. Technol. 245, 116867.

Zhang, H., Zhu, Z., Lin, J., Cheung, C. F., Lu, Y. L., Yan, F., Chan, C. Y., and Li, G. (2020) Reusable and Recyclable Graphene Masks with Outstanding Superhydrophobic and Photothermal Performances. ACS Nano 14, 6213.

Ahmed, S. R., Kang, S. W., Oh, S., Lee, J., and Neethirajan, S. (2018) Chiral zirconium quantum dots: A new class of nanocrystals for optical detection of coronavirus. *Heliyon* 4, No. e00766.

Park, T. J., Lee, S. Y., Lee, S. J., Park, J. P., Yang, K. S., Lee, K. B., Ko, S., Park, J. B., Kim, T., Kim, S. K., Shin, Y. B., Chung, B. Y., Ku, S. J., Kim, D. H., and Choi, I. S. (2006) *Anal. Chem.* 78, 7197.

Kim, H., Park, M., Hwang, J., Kim, J. H., Chung, D. R., Lee, K. S., and Kang, M. (2019) Development of Label-Free Colorimetric Assay for MERS-CoV Using Gold Nanoparticles. *ACS Sens.* 4, 1306.

Liu, I. L., Lin, Y. C., Lin, Y. C., Jian, C. Z., Chen, I. C., and Chen, H. W. (2019) A Novel Immunochromatographic Strip for Antigen Detection of Avian Infectious Bronchitis Virus. *Int. J. Mol. Sci.* 20, 2216.

Bian, H., Xu, F., Ji, Y., Wang, L., Deng, S. J., Ji, A., and Tang, Y. (2019) A new immunochromatographic assay for on-site detection of porcine epidemic diarrhea virus based on monoclonal antibodies prepared by using cell surface fluorescence immunosorbent assay. *BMC Vet. Res.* 15, 32.

Teengam, P., Sangproh, W., Tuantranont, A., Villain, T., Chailapakul, O., and Henry, C. S. (2017) Multiplex Paper-Based Colorimetric DNA Sensor Using Pyrrolidyl Peptide Nucleic Acid-Induced AgNPs Aggregation for Detecting MERS-CoV, MTB, and HPV Oligonucleotides. *Anal. Chem.* 89, 5428.

Qiu, G., Gai, Z., Tao, Y., Schmitt, J., Kullak-Ublick, G. A., and Wang, J. (2020) Dual-Functional Plamonic Photothermal Biosensors for highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection. *ACS Nano* 14, S268.

Akhrzymuk, I., Lin, S. C., Sun, M., Patnaik, A., Lehman, C., Altamura, L., Minogue, T., Lepene, B., Van Hoek, M. L., and Kehn-Hall, K. (2020) Magnetic Nanotrap Particles Preserve the Stability of Venezuelan Equine Encephalitis Virus in Blood for Laboratory Detection. *Front. Vet. Sci.* 6, 509.

Layqah, L. A., and Eissa, S. (2019) An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. *Microchim. Acta* 186, 224.

Seo, G., Lee, G., Kim, M. J., Baek, S.-H., Choi, M., Ku, K. B., Lee, C.-S., Jun, S., Park, D., Kim, H. G., Kim, S.-J., Lee, J.-O, Kim, B. T., Park, E. C., and Kim, S. I. (2020) Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano* 14, 5135.

Huang, Y., Xing, N., Wang, Z., Zhang, X., Zhao, X., Du, Q., Chang, L., and Tong, D. (2015) Ultrasensitive Detection of RNA and DNA Viruses Simultaneously Using Duplex UNDP-PCR Assay. *PLoS One* 10, No. e0141545.

Zhu, Y., Liang, L., Luo, Y., Wang, G., Wang, C., Cui, Y., Ai, X., and Cui, S. (2017) A sensitive duplex nanoparticle-assisted PCR assay for identifying porcine epidemic diarrhea virus and porcine transmissible gastroenteritis virus from clinical specimens. *Virus Genes* 53, 71.

Yuan, W., Li, Y., Li, P., Song, Q., Li, L., and Sun, J. (2015) Development of a nanoparticle-assisted PCR assay for detection of porcine epidemic diarrhea virus. *J. Virol. Methods* 220, 18.

Zhu, Y., Wang, G. H., Cui, Y. D., and Cui, S. J. (2016) Establishment of a nanoparticle-assisted RT-PCR assay to distinguish field strains and attenuated strains of porcine epidemic diarrhea virus. *Arch. Virol.* 161, 2543.

Wiley, J. A., Richert, L. E., Swain, S. D., Harmsen, A., Barnard, D. L., Randall, T. D., Jutila, M., Douglas, T., Broomell, C., Young, M., and Harmsen, A. (2009) Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses. *PLoS One* 4, No. e71422.

Clinical trial NCT04283461 accessible through https://clinicaltrials.gov.
(56) Kim, H.-M., Kim, D.-M., Jeong, C., Park, S. Y., Cha, M. G., Ha, Y., Jang, D., Kyeong, S., Pham, X.-H., Hahm, E., Lee, S. H., Jeong, D. H., Lee, Y.-S., Kim, D.-E., and Jun, B.-H. (2018) Assembly of Plasmonic and Magnetic Nanoparticles with Fluorescent Silica Shell Layer for Tri-functional SERS-Magnetic-Fluorescence Probes and Its Bioapplications. *Sci. Rep.* 8, 13938.

(57) Li, J., Helal, Z. H., Karch, C. P., Mishra, N., Girshick, T., Garmendia, A., Burkhard, P., and Khan, M. I. (2018) A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus. *PLoS One* 13, e0203771.

(58) Luke, T., Wu, H., Zhao, J., Channappanavar, R., Coleman, C. M., Jiao, J.-A., Matsushita, H., Liu, Y., Postnikova, E. N., Ork, B. L., Glenn, G., Flyer, D., Delang, G., Raviprakash, K., Kochel, T., Wang, J., Nie, W., Smith, G., Hensley, L. E., Olinger, G. G., Kuhn, J. H., Holbrook, M. R., Johnson, R. F., Perlman, S., Sullivan, E., and Frieman, M. B. (2016) Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. *Sci. Transl. Med.* 8, 326ra21.

(59) Pimentel, T. A. P. F., Yan, Z., Jeffers, S. A., Holmes, K. V., Hodges, R. S., and Burkhard, P. (2009) Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine. *Chem. Biol. Drug Des.* 73, 53.

(60) Shen, Z. T., and Sigalov, A. B. (2016) SARS Coronavirus Fusion Peptide-Derived Sequence Suppresses Collagen-Induced Arthritis in DBA/1J Mice. *Sci. Rep.* 6, 28672.

(61) Wiley, J. A., Richert, L. E., Swain, S. D., Harmsen, A., Barnard, D. L., Randall, T. D., Jutila, M., Douglas, T., Broomell, C., Young, M., and Harmsen, A. (2009) Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses. *PLoS One* 4, e7142.